MUSC Hollings Cancer Center seeks Medical University of South Carolina (MUSC) faculty who have an interest in cancer research and a desire to promote the center’s mission. Membership in Hollings Cancer Center is open to all MUSC faculty who meet the criteria listed below. Hollings Members are given priority access to Hollings Cancer Center-supported Shared Resources and are eligible to apply for pilot project funding.

For questions about membership, please contact Julia Singleton at

Member Categories


A Member is an MUSC faculty member who is actively conducting basic, translational, clinical, or population-based cancer research on a regular and ongoing basis and meets one of the following criteria:

  • Principal investigator (PI, multi-PI [MPI], or project leader) on a cancer-related, peer-reviewed, funded research grant or training grant (i.e., NIH K awards, COBRE awards, or other similar career development awards).
  • PI on an investigator-initiated, cancer-focused clinical trial or a Hollings Clinical Scholar awardee.
  • Clinician accruing a minimum of 10 patients to interventional treatment (therapeutic), cancer-focused clinical trials per year.
  • Faculty at the assistant/instructor level recruited to MUSC through support from Hollings within the past three years.
  • Faculty who play a critical role in team-based science, support the cancer center’s mission, and have a consistent record of publishing cancer-related manuscripts in peer-reviewed journals.
  • Faculty appointed to a leadership role by the director of Hollings Cancer Center.

Members are the major focus of Hollings Cancer Center scientific programs and are included on the National Cancer Institute (NCI) Cancer Center Support Grant (CCSG).


An Affiliate is:

  • An investigator, including non-faculty investigators (e.g., instructor, research associate, and non-tenure track assistant professors), who have no active, independent, cancer-related extramural funding but are interested and/or involved in cancer research; OR
  • MUSC tenured faculty working in non-cancer-related areas who is interested in making his/her research more cancer relevant; OR
  • An investigator at the University of South Carolina, Clemson University, or other higher academic institution deemed appropriate by the director who has initiated early interactions with Hollings members and participates in Hollings Cancer Center activities.

Affiliates are not included on the CCSG.

Membership Privileges

  • Members and Affiliates receive Hollings Cancer Center publications and communications.
  • Members and Affiliates may attend Hollings-sponsored conferences, seminars, and retreats at no cost.
  • Members and Affiliates appear on the Hollings website.
  • Members who hold key leadership positions are potentially eligible for salary support from Hollings.
  • Members will have priority access to shared equipment, shared resources, and services developed and/or supported by Hollings, including the Clinical Trials Office. Members and Affiliates receive a co-payment for usage of Hollings Cancer Center Shared Resources. Hollings-supported Shared Resources include:
    • Lipidomics
    • Flow Cytometry & Cell Sorting
    • Cell & Molecular Imaging
    • Biostatistics
    • Biorepository & Tissue Analysis
  • Members receive access to a peer-review mechanism (Protocol Review Committee) for scientific and technical review of oncology clinical research studies involving humans and/or human specimens/data proposed for activation.
  • Members receive access to a Data and Safety Monitoring Committee for oncology trials.
  • Members are eligible for potential Hollings Cancer Center developmental funds for research pilot projects.
  • Members are eligible for pre- and postdoctoral student research stipends.
  • Members are eligible for access to administrative support in submitting research proposals for funding.
  • Members are eligible for assignment to Hollings Cancer Center laboratory or other research space as available.

Obligations of Membership

  • Members and Affiliates must actively participate in one of the following research programs. Participation includes developing new research projects in collaboration with other program members; attendance at Hollings Cancer Center research program meetings, sponsored conferences, seminars, etc.; authorship of cancer-related manuscripts with other program members, etc.

Cancer Biology Program
Program leader: Philip H. Howe, Ph.D.

Cancer Control Program
Program co-leaders: Matthew Carpenter, Ph.D., and Jennifer Dahne, Ph.D.

Cancer Immunology Program
Program co-leaders: Shikhar Mehrotra, Ph.D., and Sophie Paczesny, M.D., Ph.D.

Developmental Cancer Therapeutics Program
Program co-leaders: Nancy Klauber-DeMore, M.D., and John O'Bryan, Ph.D.

  • Members who are clinicians must actively participate in established Hollings Cancer Center multidisciplinary clinics, tumor boards, clinical trial meetings, and other Hollings-sponsored clinical and educational programmatic activities.
  • Members and Affiliates must submit all prospective oncology studies involving humans and/or human specimens/data to Hollings’ Protocol Review Committee prior to Institutional Review Board (IRB) approval. The policies and procedures for the Protocol Review Committee are available on the Hollings Cancer Center intranet.
  • Members and Affiliates must provide information on cancer clinical studies (patient data, adverse events, protocol deviations, copies of IRB approval letters, revised protocols, audit reports, etc.) regardless of whether they utilize the Hollings Clinical Trials Office.
  • Members and Affiliates must provide copies of IRB submissions in regards to serious adverse events, protocol deviations, and audit reports regardless of whether they utilize the Hollings Clinical Trials Office.
  • Members and Affiliates’ oncology clinical trials will be reviewed semi-annually for accrual by the Protocol Review Committee. For trials not meeting their accrual goals per the committee's policy, probation letters will be issued. To avoid closure, members must respond to the probation letter by the deadline given so that the committee may review the reasonableness of the accrual corrective action plan. Members agree that this committee has the authority to close low- or non-accruing trials. The policies and procedures for the Protocol Review Committee are available on the Hollings Cancer Center intranet.
  • Members must actively participate in the preparation of the P30 Cancer Center Support Grant application to the NCI.
  • Members and Affiliates must provide information on clinical studies, publications, research support, and other information needed to fulfill P30 Cancer Center Support Grant requirements.
  • Members and Affiliates must acknowledge use of Hollings facilities, shared resources, space, or assistance (when appropriate) in research publications and new grant submissions.

Application Process

  1. Complete the Hollings Cancer Center Membership Application Form through the Hollings website and upload an NIH-formatted biosketch including extramural support (C.V. if biosketch is not available). Additional information can be obtained by contacting Julia Singleton at 843-792-5489 or
  2. Individual applications will be reviewed by Hollings leadership.
  3. Applicants will receive notification of the decision indicating their type of membership.

Review and Renewal of Applications

All Members and Affiliates will be reviewed annually by Hollings leadership, and they may reassign membership categories based on current review of category criteria and member information. Members and Affiliates must meet all the criteria listed for new applicants in their current membership category or their membership status will be reassigned. Membership recommendations will then be sent to the Hollings director for approval. The director has final authority on approval, disapproval, or termination of membership.

Definition of Peer-Reviewed, Funded Research that Meets Criteria of a Member

  • Awarded individual cancer-related research grants, cooperative agreements, and research contracts from the NCI or NIH with the following prefixes: R00, R01, R03, R15, R18, R21, R24, R25, R33, R37, R41, R42, R43, R44, R55, R56, P01, P20, P30s (other than the CCSG), P50, SC1, SC2, U01, U10, U19, U54, U56, N01; training and career development awards (i.e., NIH K awards, COBRE awards, or other similar career development awards); and Hollings Clinical Scholar awards.
  • Please see this list of Peer Review Funding Organizations (PDF) for a list of other peer-reviewing agencies.